To The East! Leo CEO On Astellas Deal And Global Ambitions
This article was originally published in PharmAsia News
The acquisition of Astellas's dermatology business for €675m ($725m) by Denmark's skin disease specialist Leo Pharma, announced Nov. 11, is as much about satisfying the company's desire to reach critical mass in certain markets, including China, as it is about reviving an aging portfolio of products.
Register for our free email digests: